Company / Operating Income
Axsome Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$166.8M
FY2025
5-year range
-$280.6M / -$124.7M
FY2021-FY2025
Trend
+40.6%
vs FY2024
Sector context
#125 of 204
Health Care
What the data says
At -$167M, Axsome Therapeutics, Inc.'s operating income ranks #125 of 204 in the Health Care sector. Operating Income returned to growth in FY2025 after 7 years of decline, reaching -$167M.
Based on SEC 10-K filings.
-$167M in FY2025.
Improved from -$232M to -$167M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#125 of 204 in Health CareTop 61% of 204This company -$166.8M Sector average $107.7M
▼
-254.8% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 40.6% year-over-year.
- Ranks #125 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2017.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$166.8M | +40.6% |
| FY2024 | -$280.6M | -21.0% |
| FY2023 | -$231.8M | -28.9% |
| FY2022 | -$179.8M | -44.2% |
| FY2021 | -$124.7M | -25.8% |
| FY2020 | -$99.1M | -47.4% |
| FY2019 | -$67.2M | -104.7% |
| FY2018 | -$32.8M | -20.9% |
| FY2017 | -$27.2M | +1.4% |
| FY2016 | -$27.5M | -199.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026